Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis

BACKGROUND: Rituximab (RTX), a B cell–depleting anti-CD20 monoclonal antibody, is approved for treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Low immunoglobulin (Ig) levels have been observed surrounding RTX treatment. The association between the degree of Ig d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Shivani, Jaggi, Khushleen, Greenberg, Keiko, Geetha, Duvuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Rituximab
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570101/
https://www.ncbi.nlm.nih.gov/pubmed/28852483
http://dx.doi.org/10.1093/ckj/sfx014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570101/
https://www.ncbi.nlm.nih.gov/pubmed/28852483
http://dx.doi.org/10.1093/ckj/sfx014

Ejemplares similares